Treatment algorithm for aCML. Please refer to “Treatment” for a discussion of this treatment scheme for aCML. This algorithm is based on several decision nodes, including the following: (1) potential candidacy for allogeneic hematopoietic stem cell transplantation (HSCT); (2) the results of myeloid mutation panel testing; (3) eligibility for enrollment in clinical trials; and (4) opportunities to adopt strategies used for MDS or MPN (eg, hypomethylating agents or second-line/adjunctive therapies). ESAs, erythropoiesis-stimulating agents. *, The ability to target certain genes is expected to change over time as new therapeutics are developed. **, Myeloid mutation panel testing may also be performed prior to patients proceeding directly to allogeneic HSCT who do not require pretransplant disease cytoreduction.